Market Overview

5 Pharmaceutical Price Target Raises From Jefferies

Related ABT
6 Big Pharma Companies Left To Report September Quarterly Figures
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
My Dividend Growth Portfolio - Q3 2016 Summary (Seeking Alpha)
Related BMY
6 Big Pharma Companies Left To Report September Quarterly Figures
Citi Launches Positive Coverage On Five Prime Therapeutics
Baron Funds Comments on Bristol-Myers Squibb Co. (GuruFocus)

Jefferies' Jeffrey Holford raised five pharmaceuticals following key news on each company's products:

  • Abbott (NYSE: ABT) increased the price target to $45.00 after Abbot reported positive results from Type-1 Diabetes study. The study showed that Abbott system's significantly reduced Hypoglycemia.
  • Bristol-Myers Squibb Company (NYSE: BMY) raised the price objective to $78.00 after the company announced new data demonstrating continued research expansion and Immuno-Oncology Advancements across multiple blood cancers. Additionally, Bristo-Myers Squibb announced new data on Opdivo which indicated benefit in heavily pre-treated classical Hodgkin Lymphoma Patients in Phase 2.
  • Johnson and Johnson (NYSE: JNJ) price target raised to $109.00 after it announced EPREX demonstrated effectiveness as treatment for Anaemia in patients with low or intermediate-1 risk of Myelodysplastic syndromes at EHA Saturday.
  • Pfizer (NYSE: PFE)'s price target rose to $42.00 after the company announced two pivotal phase 3 studies for Ertuglifozin Met Primary Endpoints, showing significant A1C reductions in patients with Type 2 Diabetes at the American Diabetes Association's 76th scientific sessions Sunday.
  • Zoetis (NYSE: ZTS) increased the price objective to $58.00 after Zoetis shares rose considerably over the last three months.

Latest Ratings for ABT

Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color News Price Target FDA Analyst Ratings


Related Articles (ABT + BMY)

View Comments and Join the Discussion!